BRD5075 is an effective activator of GPR65, stimulating the production of cAMP in a GPR65-dependent manner. Additionally, it reduces the gene expression of IL-1, IL-2, TNF, and chemokines. BRD5075 holds potential for researching multiple sclerosis and inflammatory bowel disease (IBD).
Target:
Interleukin
* VAT and and shipping costs not included. Errors and price changes excepted
